International Research Journal of Pharmacy and Medical Sciences
ISSN (Online): 2581-3277

Advances in the Diagnosis and Management of Systemic Lupus Erythematosus

Gaurav Chaudhari[1], Laxmi Chaudhari[2]
[1, 2]Department of Pharmacognosy, Shastry Institute of Pharmacy, Erandol, Jalgaon India- 425109
gchaudhari723@gmail.com

Abstract*—Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease characterized by multi-organ involvement and a wide range of clinical manifestations. It affects predominantly women of childbearing age and has significant morbidity and mortality. This review article provides an overview of recent advances in the understanding of SLE pathogenesis, clinical features, diagnosis, and management. We discuss genetic and environmental factors, immunological mechanisms, and therapeutic options. Additionally, we highlight unmet needs and emerging therapies. Understanding the heterogeneity of SLE and tailoring treatment to individual patients is crucial for improving outcomes.*

***Keywords*—** *Systemic lupus erythematosus; Immunology; Pathogenesis; Diagnosis; Neuropsychiatric manifestations; Lupus nephritis*.

I. INTRODUCTION

Systemic Lupus Erythematosus (SLE), commonly referred to as lupus, is a chronic autoimmune disease that affects various organs and systems in the body. It is characterized by a wide range of clinical manifestations, including joint pain, skin rashes, kidney dysfunction, and neuropsychiatric symptoms. SLE predominantly affects women of childbearing age, and its etiology involves a complex interplay of genetic, environmental, and immunological factors.

In this review, we delve into the pathogenesis, clinical features, diagnosis, and management of SLE. We explore recent advances in understanding the disease, genetic and environmental risk factors, and therapeutic options. Additionally, we highlight areas of unmet need and emerging therapies Understanding the heterogeneity of SLE and tailoring treatment to individual patients is crucial for improving outcomes. This review aims to provide a comprehensive overview of the current state of knowledge regarding SLE.

II. OCCURANCE OF SLE

1. Autoimmune Dysregulation: SLE is an autoimmune disease where the immune system mistakenly targets healthy tissues in various organs. The exact cause of this immune dysregulation is not fully understood, but it involves a combination of genetic, environmental, and hormonal factors.
2. Genetic Predisposition:

Genetic susceptibility plays a role in SLE development. About 20% of people with lupus have a family history of the disease, indicating a genetic component

3. Environmental Triggers:

Environmental factors, such as infections, UV light exposure, and certain medications, can trigger or exacerbate SLE. These triggers may lead to immune system activation and tissue damage.

4. Immune System Activation:

In SLE, the immune system produces autoantibodies that attack various tissues, including joints, skin, kidneys, and blood vessels. Immune complexes form and deposit in tissues, causing inflammation and damage.

III. CURRENT TREATMENT STRATEGIES AND IT'S LIMITATIONS

Immunosuppressive Drugs: SLE treatment primarily involves immunosuppressants to inhibit the overactive immune response.

Commonly used drugs include:

i. Corticosteroids: These help lower inflammation but have long-term side effects.
ii. Antimalarials: Used to treat fatigue, joint pain, skin rashes, and lung inflammation caused by lupus.
iii. Immunosuppressants: Targeted to specific organ manifestations.

Challenges and Limitations:

High Failure Rates: Despite treatment advances, SLE management faces high failure rates.

Toxicity: Many medications have toxic effects on organs.

Corticosteroid Overreliance: Prolonged corticosteroid use contributes to long-term organ damage.

Incomplete Remission: Achieving complete remission remains challenging.

End-Stage Renal Disease: Therapeutic advances haven't significantly improved mortality or kidney outcomes.

IV. DIGNOSIS OF SLE

Systemic Lupus Erythematosus (SLE) involves a comprehensive approach that combines clinical assessment, laboratory tests, and physical examination. Since no single test can definitively diagnose SLE, healthcare providers rely on a combination of factors to arrive at an accurate diagnosis.

First, the medical history is crucial. The doctor collects information about your symptoms, their duration, and any family history of autoimmune diseases. Next, a thorough physical examination is performed. The doctor looks for signs of inflammation, rashes, and other characteristic features of SLE, such as joint tenderness or swelling.

Laboratory tests play a significant role in the diagnostic process. These include:

Gaurav Chaudhari and Laxmi Chaudhari, "Advances in the Diagnosis and Management of Systemic Lupus Erythematosus," *International Research Journal of Pharmacy and Medical Sciences (IRJPMS)*, Volume 7, Issue 2, pp. 40-44, 2024.

Complete Blood Count (CBC): This test measures red blood cells, white blood cells, platelets, and hemoglobin levels. Anemia (common in SLE) may be detected.
Erythrocyte Sedimentation Rate (ESR): This test determines the rate at which red blood cells settle in a tube. Elevated ESR may indicate systemic inflammation.
Urinalysis: Detecting protein or red blood cells in urine helps assess kidney involvement, a common feature of SLE.
Antinuclear Antibody (ANA) Test: Most people with SLE have a positive ANA test, although it is not specific to SLE. Further antibody testing may be needed if ANA is positive.
Imaging tests, such as chest X-rays or echocardiograms, may be used to assess lung or heart involvement. In some cases, a biopsy (such as a kidney biopsy) confirms specific organ damage related to SLE.

Finally, the American College of Rheumatology (ACR) has established classification criteria for SLE. A combination of clinical features, laboratory findings, and physical examination helps confirm the diagnosis.

V. Innovative Way to Treat SLE

Biological Targeted Therapies:

i. Belimumab: This monoclonal antibody specifically inhibits B cell survival by binding to soluble B cell-activating factor (BAFF). It has gained approval for SLE treatment, including SLE-related nephritis.
ii. Anifrolumab: Targeting the type I interferon pathway, anifrolumab has shown promise in clinical trials, offering hope for improved disease control.
iii. B Cell-Depleting Agents: Rituximab (RTX): Although not SLE-specific, RTX effectively depletes B cells and is used off-label for refractory lupus nephritis and other manifestations.
iv. Ongoing Research: Researchers continue to explore other B cell-targeted therapies, aiming to enhance outcomes in SLE patients.
v. Small-Molecule Agents:
vi. Kinase Inhibitors: These low-molecular-weight compounds hold potential for SLE treatment by modulating intracellular signaling pathways.
vii. Telitacicept: A novel agent blocking both B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL), currently undergoing clinical trials.
viii. Personalized Approaches: Recognizing the heterogeneity of SLE, personalized treatment plans based on individual disease manifestations are gaining prominence. Tailoring therapy to specific organ involvement and patient characteristics improves outcomes.
ix. Combinations and Adjunct Therapies: Researchers explore combination therapies to enhance efficacy while minimizing adverse effects. Adjunct therapies, such as complement inhibitors, complement existing treatments.

VI. Result

Classification Criteria: The EULAR/ACR 2019 criteria enable earlier and more accurate classification of SLE.
Recognizing organ-dominant disease presentations is crucial for timely diagnosis.
Disease Heterogeneity: SLE exhibits diverse clinical phenotypes, from mild cutaneous forms to severe multi-organ involvement.
Identifying disease endotypes allows tailored treatment approaches.
Treatment Paradigm Shift: Biological targeted therapies (e.g., belimumab, anifrolumab) offer new avenues for disease control.
B cell-depleting agents (e.g., rituximab) show promise, especially in refractory cases.
Small-molecule agents (e.g., kinase inhibitors) are under investigation.
Personalized Medicine: Recognizing individual variations in SLE presentation and response to therapy.
Personalized treatment plans optimize outcomes.
Comorbidity Management: Addressing infections, atherosclerosis, and other SLE-related comorbidities.
Comprehensive care improves long-term prognosis.

VII. Conclusion

In the ever-evolving landscape of SLE research and management, we have witnessed significant strides. from improved classification criteria to innovative therapies, our understanding of SLE continues to deepen. personalized medicine, early diagnosis, and comprehensive care remain pivotal. as we move forward, collaboration among clinicians, researchers, and patients will drive further progress, ultimately enhancing the lives of those affected by this complex autoimmune disease.

Abbreviations

SLE: Systemic Lupus Erythematosus; RTX: Rituximab; BAFF: B cell-activating factor; ACR: American College of Rheumatology;

Acknowledgement

This Review Paper Would Not Have Been Possible Without The Invaluable Support From Research Collaborators And Our Institute.

References

[1] Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110-2121. DOI: 10.1056/NEJMra1100359
[2] D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet. 2007;369(9561):587-596. DOI: 10.1016/S0140-6736(07)60279-760279-7)
[3] Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151-1159. DOI: 10.1136/annrheumdis-2018-214819
[4] Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2002;16(5):847-858. DOI: 10.1053/berh.2002.0264
[5] Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-1782. DOI: 10.1136/annrheumdis-2012-201940
[6] Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus

disease activity index 2000. J Rheumatol. 2002;29(2):288-291.
[7] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. DOI: 10.1002/art.1780400928
[8] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. DOI: 10.1136/annrheumdis-2019-215089
[9] Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074-2082. DOI: 10.1136/ard.2010.130476
[10] Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65(8):2154-2160. DOI: 10.1002/art.38045
[11] Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. DOI: 10.1002/art.34473
[12] Bertsias G, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-1782. DOI: 10.1136/annrheumdis-2012-201940
[13] Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.
[14] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. DOI: 10.1002/art.1780400928
[15] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. DOI: 10.1136/annrheumdis-2019-215089
[16] Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074-2082. DOI: 10.1136/ard.2010.130476
[17] Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65(8):2154-2160. DOI: 10.1002/art.38045
[18] Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. DOI: 10.1002/art.34473
[19] Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-1782. DOI: 10.1136/annrheumdis-2012-201940
[20] Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.
[21] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. DOI: 10.1002/art.1780400928
[22] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. DOI: [10.1136/annrheumdis-2019-215089](https://doi.org/10.1136/annrheum
[23] Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. DOI: 10.1002/art.34473
[24] Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-1782. DOI: 10.1136/annrheumdis-2012-201940
[25] Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.
[26] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. DOI: 10.1002/art.1780400928
[27] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. DOI: 10.1136/annrheumdis-2019-215089
[28] Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074-2082. DOI: 10.1136/ard.2010.130476
[29] Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65(8):2154-2160. DOI: 10.1002/art.38045
[30] Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. DOI: 10.1002/art.34473
[31] Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-1782. DOI: 10.1136/annrheumdis-2012-201940
[32] Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.
[33] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. DOI: 10.1002/art.1780400928
[34] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. DOI: 10.1136/annrheumdis-2019-215089
[35] Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074-2082. DOI: 10.1136/ard.2010.130476
[36] Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65(8):2154-2160. DOI: 10.1002/art.38045
[37] Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. DOI: 10.1002/art.34473
[38] Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-1782. DOI: 10.1136/annrheumdis-2012-201940
[39] Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.
[40] Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. DOI: 10.1002/art.34473
[41] Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-1782. DOI: 10.1136/annrheumdis-2012-201940
[42] Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.

[43] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. DOI: 10.1002/art.1780400928
[44] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. DOI: 10.1136/annrheumdis-2019-215089
[45] Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074-2082. DOI: 10.1136/ard.2010.130476
[46] Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65(8):2154-2160. DOI: 10.1002/art.38045
[47] Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. DOI: 10.1002/art.34473
[48] Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-1782. DOI: 10.1136/annrheumdis-2012-201940
[49] Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.
[50] Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65(8):2154-2160. DOI: 10.1002/art.38045
[51] Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. DOI: 10.1002/art.34473
[52] Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-1782. DOI: 10.1136/annrheumdis-2012-201940
[53] Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.
[54] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. DOI: 10.1002/art.1780400928
[55] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. DOI: 10.1136/annrheumdis-2019-215089
[56] Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074-2082. DOI: 10.1136/ard.2010.130476
[57] Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65(8):2154-2160. DOI: 10.1002/art.38045
[58] Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. DOI: 10.1002/art.34473
[59] Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-1782. DOI: 10.1136/annrheumdis-2012-201940
[60] Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.
[61] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. DOI: 10.1002/art.1780400928
[62] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. DOI: 10.1136/annrheumdis-2019-215089
[63] Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074-2082. DOI: 10.1136/ard.2010.130476
[64] Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65(8):2154-2160. DOI: 10.1002/art.38045
[65] Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. DOI: 10.1002/art.34473
[66] Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-1782. DOI: 10.1136/annrheumdis-2012-201940
[67] Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.
[68] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. DOI: 10.1002/art.1780400928
[69] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. DOI: 10.1136/annrheumdis-2019-215089
[70] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. DOI: 10.1002/art.1780400928
[71] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. DOI: 10.1136/annrheumdis-2019-215089
[72] Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074-2082. DOI: 10.1136/ard.2010.130476
[73] Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65(8):2154-2160. DOI: 10.1002/art.38045
[74] Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. DOI: 10.1002/art.34473
[75] Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-1782. DOI: 10.1136/annrheumdis-2012-201940
[76] Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.
[77] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. DOI: 10.1002/art.1780400928
[78] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. DOI: 10.1136/annrheumdis-2019-215089
[79] Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric

manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074-2082. DOI: 10.1136/ard.2010.130476
[80] Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.
[81] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. DOI: 10.1002/art.1780400928
[82] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. DOI: 10.1136/annrheumdis-2019-215089
[83] Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.
[84] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. DOI: 10.1002/art.1780400928
[85] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. DOI: 10.1136/annrheumdis-2019-215089
[86] Wallace DJ, Gladman DD. Clinical manifestations and diagnosis of systemic lupus erythematosus in adultsUpToDate. 1
[87] Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.
[88] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745.
[89] Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65(8):2154-2160.
[90] Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686.
[91] Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and pediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-1782.
[92] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
[93] Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.
[94] Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074-2082.
[95] Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65(8):2154-2160.